PEDRO PABLO
ESPAÑA YANDIOLA
Investigador hasta 2024
Pfizer (United States)
Nueva York, Estados UnidosPublicaciones en colaboración con investigadores/as de Pfizer (United States) (2)
2023
-
Pneumococcal Serotypes Associated with Community-Acquired Pneumonia Hospitalizations in Adults in Spain, 2016–2020: The CAPA Study
Microorganisms, Vol. 11, Núm. 11
2017
-
The burden of PCV13 serotypes in hospitalized pneumococcal pneumonia in Spain using a novel urinary antigen detection test. CAPA study
Vaccine, Vol. 35, Núm. 39, pp. 5264-5270